Journal Article10.1128/CMR.12.1.40
Current and Emerging Azole Antifungal Agents
1.1K
TL;DR: Present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections are described and a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles is provided.
read more
Abstract: Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
New advances in antifungal treatment
TL;DR: Clinical aspects of treatment of invasive aspergillosis, infections caused by dematiaceous fungi, and mycoses caused by endemic, dimorphic fungi are described in this review.
Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.
Hideyo Yamaguchi
- 01 Jan 2016
TL;DR: Ravuconazole and its prodrugs are promising new drug candidates for oral therapy of onychomycosis, among which a water-soluble prodrug, mono-lysine phosphoester derivative (E1224 or BFE1224) is in the most advanced stage of clinical development.
Inhibition of cytochromes p450: existing and new promising therapeutic targets.
Inge Schuster,Rita Bernhardt +1 more
TL;DR: A comprehensive overview on cytochromes P450s, which are already well-established targets – particularly focussing on the treatment of infectious diseases, metabolic disorders and cancer – and on those, which have a high potential to become successful targets.
Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine
Vivek Dave,Nishant Bhardwaj,Nikita Gupta,Kajal Tak +3 more
- 06 Feb 2020
TL;DR: The complete study clearly indicates that the buildup of ethosomal formulation with luliconazole and neem extract show synergistic effect thereby, expressing excellent result against the treatment of fungal infection.
Echinocandins - an update
TL;DR: The main goal is to find glucan synthesis inhibitors with a broad spectrum of fungicidal activity and useful oral bioavailability.
References
•Book
Principles and Practice of Infectious Diseases
Gerald L. Mandell,R. Gordon Douglas,John E. Bennett +2 more
- 01 Mar 1989
TL;DR: This updated and expanded edition now offers 297 chapters that cover the basic principles of diagnosis and management, major clinical syndromes, all important pathogenic microbes and the diseases they cause, plus a number of specialised topics useful to the practitioner.
14.4K
National Committee for Clinical Laboratory Standards.
TL;DR: Many members of the Academy of Pediatrics seem to be generally unaware of the fact that the Academy has participated for ten years in a very interesting and valuable organization, the National Committee for Clinical Laboratory Standards (NCCLS).
14.1K
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
TL;DR: This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.
1.4K
The Merck Index
TL;DR: The Merck Index of Chemicals and Drugs is an encyclopedia for the Chemist, Pharmacist, Physician and Allied Professions and thumb-indexed, 8 dollars.
1.3K